SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/19/21 Cryoport, Inc. 424B5 1:588K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 424B5 Prospectus - Primary Offering or Shelf Securities HTML 360K - New Facts or Events
tm213534-1_424b5 - none - 7.8891435s |
| | |
Per Share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discount and commissions(1)
|
| | | $ | | | | | $ | | | ||
Proceeds, before expenses, to us
|
| | | $ | | | | | $ | | | |
| | |
Page
|
| |||
| | | | S-ii | | | |
| | | | S-iv | | | |
| | | | S-1 | | | |
| | | | S-7 | | | |
| | | | S-8 | | | |
| | | | S-10 | | | |
| | | | S-11 | | | |
| | | | S-12 | | | |
| | | | S-14 | | | |
| | | | S-16 | | | |
| | | | S-20 | | | |
| | | | S-29 | | | |
| | | | S-29 | | | |
| | | | S-29 | | | |
| | | | S-30 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 11 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 23 | | | |
| | | | 24 | | | |
| | | | 24 | | |
| | |
As of September 30, 2020
|
| |||||||||||||||
| | |
Actual
|
| |
Pro Forma
|
| |
Pro Forma
As Adjusted(1) |
| |||||||||
Cash and cash equivalents
|
| | | $ | 161,987,083 | | | | | $ | 56,196,003 | | | | | $ | 243,695,997 | | |
Debt: | | | | | | | | | | | | | | | | | | | |
Convertible note, net of discount of $3,844,791
|
| | | $ | 111,155,209 | | | | | $ | 111,155,209 | | | | | $ | 111,155,209 | | |
Long-term debt
|
| | | | — | | | | | | 4,682,800 | | | | | | 4,682,800 | | |
Total
|
| | | | 111,155,209 | | | | | | 115,838,009 | | | | | | 115,838,009 | | |
Stockholders’ equity: | | | | | | | | | | | | | | | | | | | |
Preferred stock, $0.001 par value; 2,500,000 shares authorized; none issued and outstanding, actual; 250,000 shares issued and outstanding, pro forma and pro forma as adjusted
|
| | | | — | | | | | | 250 | | | | | | 250 | | |
Common stock, par value $0.001 per share; 100,000,000 shares authorized; 38,983,824 shares issued and outstanding, actual; 39,659,360 shares issued and outstanding, pro forma; 42,782,408 shares issued and outstanding, pro forma as adjusted
|
| | | | 38,984 | | | | | | 39,660 | | | | | | 42,783 | | |
Additional paid-in capital
|
| | | | 300,273,819 | | | | | | 563,861,731 | | | | | | 763,858,602 | | |
Accumulated deficit
|
| | | | (180,483,423) | | | | | | (183,854,284) | | | | | | (183,854,284) | | |
Accumulated other comprehensive income
|
| | | | 206,626 | | | | | | 206,626 | | | | | | 206,626 | | |
Total stockholders’ equity
|
| | | | 120,036,006 | | | | | | 380,253,983 | | | | | | 580,253,977 | | |
Total capitalization
|
| | | $ | 231,191,215 | | | | | $ | 496,091,992 | | | | | $ | 396,091,986 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 64.04 | | |
|
Historical net tangible book value per share as of September 30, 2020
|
| | | $ | 2.67 | | | | | | | | |
|
Pro forma adjustment in historical net tangible book value per share attributable to the pro forma transactions described above
|
| | | $ | (2.11) | | | | | | | | |
|
Pro forma net tangible book value per share as of September 30, 2020
|
| | | $ | 0.56 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | 4.34 | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share after this offering
|
| | | | | | | | | $ | 4.90 | | |
|
Dilution per share to new investors participating in this offering
|
| | | | | | | | | $ | 59.14 | | |
UNDERWRITER
|
| |
NUMBER OF SHARES
|
| |||
Morgan Stanley & Co. LLC
|
| | | | | | |
Jefferies LLC
|
| | | | | | |
SVB Leerink LLC
|
| | | | | | |
UBS Securities LLC
|
| | | | | | |
Total
|
| | | | | | |
| | |
Per Share
|
| |
Total
|
| ||||||||||||||||||
| | |
Without
option to purchase additional shares |
| |
With
option to purchase additional shares |
| |
Without
option to purchase additional shares |
| |
With
option to purchase additional shares |
| ||||||||||||
Public offering price
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Underwriting discounts and commissions paid by us
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 11 | | | |
| | | | | 18 | | | |
| | | | | 19 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 24 | | |
This ‘424B5’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 1/19/21 | 8-K | ||
1/15/21 | ||||
1/14/21 | ||||
12/31/20 | 10-K, 4, SD | |||
12/15/20 | S-3ASR | |||
12/14/20 | 8-K/A | |||
10/1/20 | 3, 8-K, 8-K/A | |||
9/30/20 | 10-Q, 4 | |||
9/17/20 | ||||
8/24/20 | 8-K | |||
6/30/20 | 10-Q, 4 | |||
5/21/20 | 8-K | |||
3/31/20 | 10-Q, 4 | |||
12/31/19 | 10-K, 4 | |||
1/1/19 | ||||
12/31/18 | 10-K, 4, D/A | |||
3/15/05 | ||||
12/11/00 | ||||
List all Filings |